All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
Featured:
Mikkael A. SekeresDuring the 63rd ASH Annual Meeting and Exposition, the MDS Hub was pleased to speak to Mikkael Sekeres, Sylvester Comprehensive Cancer Center, Miami, US. We asked, What do the PANTHER trial results tell us about first-line treatment for high-risk myelodysplastic syndromes (MDS)?
What do the PANTHER trial results tell us about first-line treatment for high-risk MDS?
In this video, Sekeres discusses the randomized phase III PANTHER trial (NCT03268954), which investigated pevonedistat + azacitidine versus single-agent azacitidine as first-line treatment for patients with higher risk MDS, chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous leukemia (AML).
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
